Drugs to Watch report: 15 blockbusters for 2023
Clarivate study highlights treatments with blockbuster potential | IV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer make the list | Nine blockbusters from China also predicted.
Gilead avoids $1.2bn patent clash at SCOTUS
Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.
Bardehle Pagenberg boosts litigation team with senior hire
German IP specialist gears up for UPC with experienced partner | Patent litigator previously led practice at IP boutique Meissner Bolte.
Oxford University startup ordered to pay royalties
‘Rare’ case included ‘campaigning element’ says judge | Ex-student sought clarification on royalties from university | 651-paragraph ruling required Oxford Uni to justify its IP policies.
Abbott secures $26m damages in TM clash
Distributors and pharmacies face millions in damages and costs after selling international versions of Abbott products in the US | Fraud upon the court discovered after a court-authorised search of defendant’s premises seized an email server.
Viking Therapeutics accuses Chinese company of trade secret theft
California-based company alleges competitor stole secrets following a collaboration bid | Complaint says Chinese competitor founded a sister company to develop rival treatment for metabolic disorders.
Minneapolis law firm gains new partner
Addition is a former chair of a patent practice group | New partner has expertise in complex disputes over medical devices | Barnes & Thornburg | Patterson Thuente Pedersen.
US govt bodies unite to battle fake pharma
Counterfeit medicine and drugs cause more than one million deaths a year | Trio of bodies will work jointly together | National Intellectual Property Rights Coordination Center | Homeland Security Investigations.
Jazz urges Fed Circuit to undo delisting injunction
Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.
WTO waiver decision postponed
Members agreed to a partial waiver of patent protection for COVID-19 vaccines | Latest delay follows a similar decision by the US | WTO accused of “failure”.
